China's Pharmaceutical Companies Turn Attention to Monoclonal Antibodies
China's Pharmaceutical Companies Turn Attention to Monoclonal Antibodies
Attachment: China mAbs 0621
BEIJING, CHINA--Researched by Industrial Info Resources (Sugar Land, Texas)--According to the quarterly financial reports from China's listed pharmaceutical companies, Jiangsu Hengrui Medicine Company Limited has 40 new drugs under development, the most of any Chinese firm, followed by Jiangsu Chia Tai-Tianqing Pharmaceutical Company Limited with 34, and Shanghai Junshi Biosciences Company Limited with 20.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects
- U.S. Home to Billions' Worth of 2Q ESG Project Kickoffs
- Japan Hosts $832 Million in CDMO/CMO-Related Pharma Projects
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
